Want to see HK:1498 full AI Analyst Report?
1498 Stock Chart & Stats
HK$0.35
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$0.35
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$0.23 - HK$0.46
Previous CloseN/A
Volume23.50K
Average Volume (3M)65.21K
Market Cap
HK$132.13M
Enterprise ValueHK$517.12
Total Cash (Recent Filing)HK$12.23M
Total Debt (Recent Filing)HK$370.62M
Price to Earnings (P/E)―
Beta0.33
Next Earnings
Mar 31, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.48%
Share Statistics
EPS (TTM)-0.06
Shares Outstanding535,897,640
10 Day Avg. Volume92,425
30 Day Avg. Volume65,208
Financial Highlights & Ratios
PEG Ratio0.68
Price to Book (P/B)1.14
Price to Sales (P/S)0.44
P/FCF Ratio5.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginsGross margins near 53% indicate that the company retains substantial value after product costs across several years. This provides a durable base for funding selling, administrative, and development activities, although profitability still depends on controlling expenses and improving below-the-line results.
Positive Cash GenerationPositive operating and free cash flow across four consecutive years demonstrates that the business has generated cash despite reported accounting losses. This supports ongoing operations and investment capacity, though the sharp 2025 decline shows that cash conversion remains volatile rather than consistently strong.
Proprietary Products And Distribution NetworkControl across product development, manufacturing, commercialization, and distribution gives PuraPharm an integrated operating model. Its proprietary formulations and access to multiple healthcare channels can support recurring commercial reach and brand development over time, subject to actual demand and execution.
Bears Say
Persistent Net LossesRepeated EBIT and net losses show that strong gross margins have not translated into sustainable bottom-line profitability. Continued losses can limit retained capital and make the company more dependent on operating improvements, while the negative 2025 net margin leaves little evidence of a durable earnings base.
Multi-Year Revenue ContractionSeveral years of revenue contraction indicate weaker scale and limit the operating leverage available to the business. Shrinking sales make it harder to absorb fixed costs, sustain investment, or convert the company’s product portfolio and distribution network into consistently improving earnings.
Elevated And Worsening LeverageHigh leverage alongside declining equity increases balance-sheet risk and reduces financial flexibility. The capital base is under pressure from ongoing losses, leaving less room to absorb operational weakness or fund growth internally and making financial improvement more important over the coming quarters.
PuraPharm Corp. Ltd. News
1498 FAQ
What was PuraPharm Corp. Ltd.’s price range in the past 12 months?
PuraPharm Corp. Ltd. lowest stock price was HK$0.23 and its highest was HK$0.46 in the past 12 months.
What is PuraPharm Corp. Ltd.’s market cap?
PuraPharm Corp. Ltd.’s market cap is HK$132.13M.
When is PuraPharm Corp. Ltd.’s upcoming earnings report date?
PuraPharm Corp. Ltd.’s upcoming earnings report date is Mar 31, 2027 which is in 188 days.
How were PuraPharm Corp. Ltd.’s earnings last quarter?
PuraPharm Corp. Ltd. released its earnings results on Aug 26, 2026. The company reported -HK$0.027 earnings per share for the quarter.
Is PuraPharm Corp. Ltd. overvalued?
According to Wall Street analysts PuraPharm Corp. Ltd.’s price is currently Overvalued.
Does PuraPharm Corp. Ltd. pay dividends?
PuraPharm Corp. Ltd. pays a Annually dividend of HK$0.019 which represents an annual dividend yield of 0.48%. See more information on PuraPharm Corp. Ltd. dividends here
What is PuraPharm Corp. Ltd.’s EPS estimate?
PuraPharm Corp. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PuraPharm Corp. Ltd. have?
PuraPharm Corp. Ltd. has 535,897,640 shares outstanding.
What happened to PuraPharm Corp. Ltd.’s price movement after its last earnings report?
PuraPharm Corp. Ltd. reported an EPS of -HK$0.027 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of PuraPharm Corp. Ltd.?
Currently, no hedge funds are holding shares in HK:1498
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PuraPharm Corp. Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.69%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3.10%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
PuraPharm Corp. Ltd.
PuraPharm Corporation Limited, an investment holding entity, focuses on the research, development, manufacturing, and global distribution of concentrated Chinese medicine granules (CCMG) and various Chinese healthcare products across Hong Kong, Mainland China, and international markets. Its operations are structured into five key divisions: China CCMG, Hong Kong CCMG, Chinese Healthcare Products, Clinics, and Plantation. The company offers a range of over-the-counter health solutions under brand names such as PuraGold, Haveron, Oncozac, and Immuzac. Beyond product sales, PuraPharm provides a clinic management system for general Chinese medical practices and operates its own chain of Nong's Chinese medicine clinics, which deliver both traditional medical services and CCMG products. The company also oversees the cultivation and trade of raw Chinese herbs, in addition to manufacturing and selling traditional Chinese medicine decoction pieces. Complementing its product offerings, it delivers modernized Chinese medicine services and diagnostic consultations. PuraPharm distributes its goods to hospitals, healthcare institutions, medical professionals, and directly to consumers via an online store. The company currently manages 43 Nong's clinics in Hong Kong and one in Guangxi, China. Founded in 1998, its headquarters are located in Tai Po, Hong Kong.
Technical Analysis
Extrawell Pharmaceutical Holdings Limited
―
Wai Yuen Tong Medicine Holdings Limited
―
Lee's Pharmaceutical Holdings Limited
―
Pak Fah Yeow International Limited
―
Golden Throat Holdings Group Co Ltd
―